Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)

NCT04744831 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT04744831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04744831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Completed
Start date
March 5, 2021
Completion date
December 4, 2024
Enrollment
122 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer